Document is current
Any future updates will be listed below
-
Authors
Koko, Victor S. https://orcid.org/0000-0003-3774-1219
Warsame, Marian
Vonhm, Benjamin
Jeuronlon, Moses K.
Menard, Didier
Ma, Laurence
Taweh, Fahn
Tehmeh, Lekilay
Nyansaiye, Paye
Pratt, Oliver J.
Parwon, Sei
Kamara, Patrick
Asinya, Magnus
Kollie, Aaron
Ringwald, Pascal
-
Clinical Trials BETA
Clinical trials referenced in this document:
actrn12617001064392 at Australian New Zealand Clinical Trials RegistryDocuments that mention this clinical trial
Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers
https://doi.org/10.1186/s12936-022-04140-7
-
Funding
Funding for this research was provided by:
Global Fund to Fight AIDS, Tuberculosis and Malaria (FR957LBRM)
Bill and Melinda Gates Foundation (OPP1140599)
French Government (Agence Nationale de la Recherche) Investissement d’Avenir programme, Laboratoire d’Exceellence (LabEx) “Frech Parasitology Alliance For Health Care (ANR-11-LABX-0024-PARAFRAP)
- License Information
-
More Information
Article History
Received: 17 November 2021
Accepted: 27 March 2022
First Online: 27 April 2022
Declarations
:
: The study was reviewed and approved by the University of Liberia-Pacific Institute for Research & Evaluation the Institution Review Board (UL-PIRE IRB_FWA00004982) and the WHO Research Ethics Review Committee (ERC.0002892). Written informed consent was obtained from parent/guardian before enrolling their children in the study.
: Not applicable.
: The authors declare that they have no competing interests.
